Search academic texts

Information × Registration Number 0221U106632, (0120U104095) , R & D reports Title Study of coronavirus SARS-CoV-2 protein immunogenic properties as a basis for COVID19 vaccine development. popup.stage_title Дослідження антигенних властивостей рекомбінантних протеїнів SARS-CoV-2 і захисних властивостей антитіл проти них. Розробка оптимального складу вакцинного препарату проти COVID19 і проведення випробувань на тваринних моделях його дослідного зразка. Head Kolybo Denys V., Доктор біологічних наук Registration Date 16-12-2021 Organization Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine popup.description1 The aim of the project is to study the immunogenic properties of recombinant SARS-CoV-2 coronavirus proteins and their conjugates with recombinant highly immunogenic carriers capable of active transport of proteins into cells using different adjuvants for immunization, as well as to develop the optimal composition of COVID19 vaccine and to conduct preclinical studies of vaccine prototype. popup.description2 Data on compliance of antigenic properties of the recombinant and natural SARS-CoV-2 proteins, as well as the protective properties of antibodies against the recombinant SARS-CoV-2 proteins were obtained. The optimal composition of the COVID19 vaccine has been developed and preclinical trials of its prototype have been performed. It has been shown that antibodies against RBD of S protein and antibodies against RBD–CRM197 fusion protein have greater protective properties then anti-N protein antibodies. The COVID19 vaccine prototype based on the recombinant RBD–CRM197 fusion protein, which has a more stable conformation than RBD, has been developed. It has been shown that N protein can be included into the vaccine if there is evidence of its safety as a component capable of causing inflammation and an overreaction of the immune system. Animal studies have shown that the developed COVID19 vaccine prototype is characterized by sufficient immunogenicity, good local tolerability and low toxicity in doses used for immunization. The results of the project can be a starting point for clinical trials and introduction of the recombinant COVID19 vaccine into production in Ukraine.  Product Description popup.authors Horbаtiuk Oksаnа B. Guzyk Mykhailo M. Komisarenko Serhii V. Korchynskiy Oleksandr H. Krynina Olha I. Romaniuk Svitlana I. Siromolot Andrii A. popup.nrat_date 2021-12-16 Close

Information × Registration Number 0221U106632, (0120U104095) , R & D reports Title Study of coronavirus SARS-CoV-2 protein immunogenic properties as a basis for COVID19 vaccine development. popup.stage_title Дослідження антигенних властивостей рекомбінантних протеїнів SARS-CoV-2 і захисних властивостей антитіл проти них. Розробка оптимального складу вакцинного препарату проти COVID19 і проведення випробувань на тваринних моделях його дослідного зразка. Head Kolybo Denys V., Доктор біологічних наук Registration Date 16-12-2021 Organization Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine popup.description1 The aim of the project is to study the immunogenic properties of recombinant SARS-CoV-2 coronavirus proteins and their conjugates with recombinant highly immunogenic carriers capable of active transport of proteins into cells using different adjuvants for immunization, as well as to develop the optimal composition of COVID19 vaccine and to conduct preclinical studies of vaccine prototype. popup.description2 Data on compliance of antigenic properties of the recombinant and natural SARS-CoV-2 proteins, as well as the protective properties of antibodies against the recombinant SARS-CoV-2 proteins were obtained. The optimal composition of the COVID19 vaccine has been developed and preclinical trials of its prototype have been performed. It has been shown that antibodies against RBD of S protein and antibodies against RBD–CRM197 fusion protein have greater protective properties then anti-N protein antibodies. The COVID19 vaccine prototype based on the recombinant RBD–CRM197 fusion protein, which has a more stable conformation than RBD, has been developed. It has been shown that N protein can be included into the vaccine if there is evidence of its safety as a component capable of causing inflammation and an overreaction of the immune system. Animal studies have shown that the developed COVID19 vaccine prototype is characterized by sufficient immunogenicity, good local tolerability and low toxicity in doses used for immunization. The results of the project can be a starting point for clinical trials and introduction of the recombinant COVID19 vaccine into production in Ukraine.  Product Description popup.authors Horbаtiuk Oksаnа B. Guzyk Mykhailo M. Komisarenko Serhii V. Korchynskiy Oleksandr H. Krynina Olha I. Romaniuk Svitlana I. Siromolot Andrii A. popup.nrat_date 2021-12-16 Close